Med Life Future Growth

Future criteria checks 5/6

Med Life is forecast to grow earnings and revenue by 92.9% and 11.5% per annum respectively. EPS is expected to grow by 93.7% per annum. Return on equity is forecast to be 24.4% in 3 years.

Key information

92.9%

Earnings growth rate

93.7%

EPS growth rate

Healthcare earnings growth24.4%
Revenue growth rate11.5%
Future return on equity24.4%
Analyst coverage

Low

Last updated27 Nov 2024

Recent future growth updates

Recent updates

Is Med Life S.A. (BVB:M) Trading At A 41% Discount?

Aug 06
Is Med Life S.A. (BVB:M) Trading At A 41% Discount?

The Market Lifts Med Life S.A. (BVB:M) Shares 25% But It Can Do More

Jun 08
The Market Lifts Med Life S.A. (BVB:M) Shares 25% But It Can Do More

Is Med Life (BVB:M) A Risky Investment?

Apr 05
Is Med Life (BVB:M) A Risky Investment?

Returns On Capital Signal Tricky Times Ahead For Med Life (BVB:M)

Jul 05
Returns On Capital Signal Tricky Times Ahead For Med Life (BVB:M)

Is Med Life (BVB:M) A Risky Investment?

Jan 06
Is Med Life (BVB:M) A Risky Investment?

Med Life (BVB:M) Hasn't Managed To Accelerate Its Returns

Dec 06
Med Life (BVB:M) Hasn't Managed To Accelerate Its Returns

We Think Med Life (BVB:M) Is Taking Some Risk With Its Debt

Sep 27
We Think Med Life (BVB:M) Is Taking Some Risk With Its Debt

Returns Are Gaining Momentum At Med Life (BVB:M)

May 05
Returns Are Gaining Momentum At Med Life (BVB:M)

Is There An Opportunity With Med Life S.A.'s (BVB:M) 49% Undervaluation?

Mar 01
Is There An Opportunity With Med Life S.A.'s (BVB:M) 49% Undervaluation?

Med Life (BVB:M) Shareholders Will Want The ROCE Trajectory To Continue

Jan 22
Med Life (BVB:M) Shareholders Will Want The ROCE Trajectory To Continue

Does Med Life (BVB:M) Have A Healthy Balance Sheet?

Aug 31
Does Med Life (BVB:M) Have A Healthy Balance Sheet?

Med Life's (BVB:M) Returns On Capital Are Heading Higher

Jun 10
Med Life's (BVB:M) Returns On Capital Are Heading Higher

Here's Why We Think Med Life (BVB:M) Is Well Worth Watching

May 26
Here's Why We Think Med Life (BVB:M) Is Well Worth Watching

Is Now An Opportune Moment To Examine Med Life S.A. (BVB:M)?

May 12
Is Now An Opportune Moment To Examine Med Life S.A. (BVB:M)?

Is There An Opportunity With Med Life S.A.'s (BVB:M) 24% Undervaluation?

Apr 12
Is There An Opportunity With Med Life S.A.'s (BVB:M) 24% Undervaluation?

Update: Med Life (BVB:M) Stock Gained 98% In The Last Year

Mar 16
Update: Med Life (BVB:M) Stock Gained 98% In The Last Year

Should We Be Excited About The Trends Of Returns At Med Life (BVB:M)?

Mar 04
Should We Be Excited About The Trends Of Returns At Med Life (BVB:M)?

Should You Be Impressed By Med Life S.A.'s (BVB:M) ROE?

Feb 20
Should You Be Impressed By Med Life S.A.'s (BVB:M) ROE?

Med Life (BVB:M) Seems To Use Debt Quite Sensibly

Feb 07
Med Life (BVB:M) Seems To Use Debt Quite Sensibly

Is It Too Late To Consider Buying Med Life S.A. (BVB:M)?

Jan 25
Is It Too Late To Consider Buying Med Life S.A. (BVB:M)?

Do Med Life's (BVB:M) Earnings Warrant Your Attention?

Jan 08
Do Med Life's (BVB:M) Earnings Warrant Your Attention?

Is Med Life S.A. (BVB:M) Trading At A 22% Discount?

Dec 23
Is Med Life S.A. (BVB:M) Trading At A 22% Discount?

Did You Miss Med Life's (BVB:M) 49% Share Price Gain?

Dec 08
Did You Miss Med Life's (BVB:M) 49% Share Price Gain?

The Trends At Med Life (BVB:M) That You Should Know About

Nov 24
The Trends At Med Life (BVB:M) That You Should Know About

Earnings and Revenue Growth Forecasts

BVB:M - Analysts future estimates and past financials data (RON Millions)
DateRevenueEarningsFree Cash FlowCash from OpAvg. No. Analysts
12/31/20263,301187442N/A1
12/31/20252,94789314N/A1
12/31/20242,62624N/AN/A1
9/30/20242,5662210272N/A
6/30/20242,4611826274N/A
3/31/20242,33711-15223N/A
12/31/20232,2224-36184N/A
9/30/20232,116-1140268N/A
6/30/20232,020-3-10179N/A
3/31/20231,9211223212N/A
12/31/20221,8103215185N/A
9/30/20221,7256410112N/A
6/30/20221,6238083202N/A
3/31/20221,52098122209N/A
1/1/20221,438103130227N/A
9/30/20211,359107103185N/A
6/30/20211,29511267172N/A
3/31/20211,1608347148N/A
1/1/20211,0875740129N/A
9/30/20201,0333649145N/A
6/30/20209741677134N/A
3/31/20201,0071863113N/A
12/31/20199751454107N/A
9/30/2019939203276N/A
6/30/2019902162871N/A
3/31/201986111N/AN/AN/A
1/1/201980413-152N/A
9/30/20187458047N/A
6/30/20186995N/A41N/A
3/31/20186575N/AN/AN/A
1/1/20186284N/A36N/A
9/30/20176103N/A42N/A
6/30/2017577-2N/A39N/A
3/31/2017539-6N/AN/AN/A
1/1/2017508-5N/A43N/A
9/30/2016469-1N/A39N/A
12/31/20153969N/A42N/A
12/31/20143377N/A36N/A
12/31/2013306-4N/A23N/A

Analyst Future Growth Forecasts

Earnings vs Savings Rate: M's forecast earnings growth (92.9% per year) is above the savings rate (6.3%).

Earnings vs Market: M's earnings (92.9% per year) are forecast to grow faster than the RO market (-0.3% per year).

High Growth Earnings: M's earnings are expected to grow significantly over the next 3 years.

Revenue vs Market: M's revenue (11.5% per year) is forecast to grow faster than the RO market (1.5% per year).

High Growth Revenue: M's revenue (11.5% per year) is forecast to grow slower than 20% per year.


Earnings per Share Growth Forecasts


Future Return on Equity

Future ROE: M's Return on Equity is forecast to be high in 3 years time (24.4%)


Discover growth companies

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2024/12/18 23:56
End of Day Share Price 2024/12/18 00:00
Earnings2024/09/30
Annual Earnings2023/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .

Analyst Sources

Med Life S.A. is covered by 5 analysts. 1 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Caius RapanuErste Group Bank AG
Catalin DiaconuRaiffeisen Bank International AG - Institutional Equity
Cristian PopescuSwiss Capital SA